NEW YORK (GenomeWeb) Interleukin Genetics' decision to stop selling a genetic test it claims can assess the risk of gum disease is welcome news for some experts in the field of dentistry who have long had serious concerns about the science underlying the product. <\/p>\n
They contend that the test should have never come to market in the first place, but remained available to patients far too long because the leadership at Interleukin had influence within the dental research community, a group that is not well-enough versed in genetics to be able to parse the available data themselves. <\/p>\n
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story. <\/p>\n
Try GenomeWeb Premium now. <\/p>\n
Already a GenomeWeb Premium member? Login Now. Or, See if your institution qualifies for premium access. <\/p>\n
*Before your trial expires, well put together a custom quote with your long-term premium options. <\/p>\n
<\/p>\n
Read more from the original source: NEW YORK (GenomeWeb) Interleukin Genetics' decision to stop selling a genetic test it claims can assess the risk of gum disease is welcome news for some experts in the field of dentistry who have long had serious concerns about the science underlying the product. They contend that the test should have never come to market in the first place, but remained available to patients far too long because the leadership at Interleukin had influence within the dental research community, a group that is not well-enough versed in genetics to be able to parse the available data themselves. A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more Continue reading
\nControversial Gum Disease Risk Test Highlights Precision Medicine Marketing, Regulatory Issues - GenomeWeb<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"